Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
100 participants
INTERVENTIONAL
2007-07-31
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy
NCT00423059
Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration
NCT00556348
The Effect of Bevacizumab (Avastin) on Pterygium
NCT00592176
Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.
NCT01860586
Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization
NCT00555594
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Intravitreal injections with anti-VEGF agents (ex. Avastin for our trial) seem to be an important tool for certain difficult situations in which at the ocular fundus, out of different reasons (advanced age, diabetes mellitus, retinal veins occlusions, etc)new pathologic vessels appear, causing devastating changes in the posterior and anterior segment as well.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A,1, II
Avastin
2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Avastin
2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* distance acuity \< 0.5
* age \> 20 years
Exclusion Criteria
* ocular infections / inflammations
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ophthalmological Association Edelweiss
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ophthalmological Association Edelweiss
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
NARCISA IANOPOL, researcher
Role: PRINCIPAL_INVESTIGATOR
Ophthalmological Association Edelweiss
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ochiul Diabetic
Iași, , Romania
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SITE-App
Identifier Type: -
Identifier Source: secondary_id
AVAST-ro-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.